Literature DB >> 10686082

Continuous infusion of cyclosporin A postinjury significantly ameliorates cortical damage following traumatic brain injury.

P G Sullivan1, M Thompson, S W Scheff.   

Abstract

Traumatic brain injury (TBI) results in the rapid necrosis of cortical tissue at the site of injury. In the ensuing hours and days, secondary injury exacerbates the original damage resulting in significant neurological dysfunction. Recent reports from our lab demonstrate that a bolus injection of the immunosuppressant cyclosporin A (CsA) is neuroprotective following TBI. CsA transiently inhibits the opening of the mitochondrial permeability transition pore and maintains calcium homeostasis in isolated mitochondria. The present study utilized a unilateral controlled cortical impact model of TBI to assess whether the neuroprotective effects of CsA could be extended by chronic infusion. Adult rats were subjected to a moderate (2 mm) cortical deformation and the extent of cortical damage was assessed using modern stereological techniques. Animals were administrated a 20 mg/kg intraperitoneal bolus of CsA or vehicle 15 min postinjury and osmotic minipumps were implanted subcutaneously to deliver CsA (4.5 or 10 mg/kg/day) or vehicle. All animals receiving CsA demonstrated a significant reduction in lesion volume, with the highest dose offering the most neuroprotection (74% reduction in lesion volume). These results extend our previous findings and demonstrate that chronic infusion of CsA is neuroprotective following TBI. These findings also suggest that the mechanisms responsible for tissue necrosis following TBI are amenable to manipulation. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10686082     DOI: 10.1006/exnr.1999.7282

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  56 in total

1.  Blood-brain barrier pathophysiology in traumatic brain injury.

Authors:  Adam Chodobski; Brian J Zink; Joanna Szmydynger-Chodobska
Journal:  Transl Stroke Res       Date:  2011-12       Impact factor: 6.829

2.  Therapeutic window analysis of the neuroprotective effects of cyclosporine A after traumatic brain injury.

Authors:  Patrick G Sullivan; Andrea H Sebastian; Edward D Hall
Journal:  J Neurotrauma       Date:  2011-02-02       Impact factor: 5.269

Review 3.  Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies.

Authors:  David J Loane; Alan I Faden
Journal:  Trends Pharmacol Sci       Date:  2010-10-29       Impact factor: 14.819

4.  A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model.

Authors:  Stephanie N Thompson; Kimberly M Carrico; Ayman G Mustafa; Mona Bains; Edward D Hall
Journal:  J Neurotrauma       Date:  2010-12       Impact factor: 5.269

5.  Establishing a Clinically Relevant Large Animal Model Platform for TBI Therapy Development: Using Cyclosporin A as a Case Study.

Authors:  Susan S Margulies; Todd Kilbaugh; Sarah Sullivan; Colin Smith; Kathleen Propert; Melissa Byro; Kristen Saliga; Beth A Costine; Ann-Christine Duhaime
Journal:  Brain Pathol       Date:  2015-05       Impact factor: 6.508

Review 6.  Mechanisms of impaired mitochondrial energy metabolism in acute and chronic neurodegenerative disorders.

Authors:  Lucian Soane; Sibel Kahraman; Tibor Kristian; Gary Fiskum
Journal:  J Neurosci Res       Date:  2007-11-15       Impact factor: 4.164

7.  Emerging molecular therapeutic targets for spinal cord injury.

Authors:  Shuo Wang; George M Smith; Michael E Selzer; Shuxin Li
Journal:  Expert Opin Ther Targets       Date:  2019-09-04       Impact factor: 6.902

8.  Cognitive assessment of pycnogenol therapy following traumatic brain injury.

Authors:  Stephen W Scheff; Kelly N Roberts
Journal:  Neurosci Lett       Date:  2016-10-11       Impact factor: 3.046

9.  Role of cyclophilin D-dependent mitochondrial permeability transition in glutamate-induced calcium deregulation and excitotoxic neuronal death.

Authors:  Viacheslav Li; Tatiana Brustovetsky; Nickolay Brustovetsky
Journal:  Exp Neurol       Date:  2009-02-21       Impact factor: 5.330

10.  Dosing and safety of cyclosporine in patients with severe brain injury.

Authors:  Jimmi Hatton; Bonnie Rosbolt; Philip Empey; Richard Kryscio; Byron Young
Journal:  J Neurosurg       Date:  2008-10       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.